Search Browse Earnings

BioAtla, Inc.

Nasdaq:BCAB

Biological Products, (No Diagnostic Substances)·SAN DIEGO, CA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

BioAtla, Inc. — SlamSEC

Revenue

$300,000

+0.0% YoY

FY 2022

Adj. EBITDA

-$128.5M

-42822.0% margin

FY 2024

Net Income

-$123.5M

-41154.0% margin

FY 2024

EPS (Diluted)

-$2.58

FY 2024

Stock Price

$0.19

+10.1%

2026-03-09

52W Range

$0.13 – $1.43

P/E Ratio

-0.1x

Market Cap

$6.1M

Cash

$111.5M

FY 2024

Total Debt

—

Net Cash

$111.5M

FY 2022

Enterprise Value

-$105.4M

Debt / EBITDA

0.9x

FY 2022

EV / EBITDA

0.8x

Employees

—